ClinicalTrials.gg
RecruitingNCT06545409SPRATSUpdated Mar 25, 2025

Serratus Posterior Superior Intercostal Plane Block in Robotic-Assisted Thymectomy

An interventional study of Ultrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with 0.25% bupivacaine and Ultrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with a placebo solution (0.9% NaCl) in RATS Surgery, Thymectomy and Locoregional Anesthesia, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Thymoma with a site in Italy — 2 open to participants now, 4 under way, none of them phase 3. Thymoma · Italy.

Planned enrollment
11th of 11
28 · median 60
Started
2025
the only one that year
No phase
Only one
of the 13
Registered
12th of 13
by date
Lead sponsor
1 of 13
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Among the 13 studies in Thymoma with a site in Italy, this one is the 11th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is the only one with no phase, and was the 12th registered.

Thymoma

133 studies on the registry are indexed under Thymoma; 37 are open to participants now.

Browse Thymoma studies →

Open to participants now

2 of the 13 studies in Thymoma with a site in Italy are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 25 Thymoma studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Thymoma with a site in Italy, or all of them as a file.
02

Study summary

This study aims to assess the effectiveness of the Serratus Posterior Superior Intercostal Plane Block (SPSIP Block) for postoperative pain control, reducing opioid analgesic consumption, minimizing postoperative respiratory complications, and enhancing patient satisfaction (measured using the QoR-15 index) in patients undergoing robotic thymectomy, compared to patients who do not receive the block.

Read the detailed description

All patients enrolled in the study will receive the SPSIP Block under ultrasound guidance 15 minutes before entering the operating room. The SPSIP Block will be performed by the attending anesthetist (investigator 1), who will use a syringe pre-filled with 30 ml of a solution prepared in advance by another investigator (investigator 2). According to the randomization scheme, the solution in the syringe used for the SPSIP Block will contain either 0.25% bupivacaine for 50% of the cases (SPSIP group) or sterile saline solution (0.9% NaCl) for the remaining 50% of the cases (control group). Postoperatively, data collection will be managed by a third investigator (investigator 3). Neither the investigator 1, the patient, nor the investigator 3 will be informed of the syringe's contents, ensuring the study is conducted blind.

All patients enrolled in the study will receive 1000 mg of paracetamol and 30 mg of ketorolac at the end of the surgery, during skin closure. Additionally, upon arrival in the recovery room, all patients will be connected to a PCA (Patient Controlled Analgesia) pump filled with a solution containing opioids. Patients who have NPRS scores greater than 4 during postoperative pain reassessments, despite PCA use, will be given a rescue analgesic dose of 1000 mg of paracetamol (which can be repeated after 8 hours, up to a maximum of 3000 mg in 24 hours).

Postoperative pain intensity will be assessed by investigator 3 at 0, 2, 6, 12, and 24 hours after the end of surgery using the Numeric Pain Rating Scale (NPRS). Assessments will be conducted both at rest and during coughing. Total opioid and rescue analgesic consumption, incidence of postoperative complications, and length of hospital stay will also be recorded. Twenty-four hours after the surgery, investigator 3 will administer the Quality of Recovery 15 (QoR-15) questionnaire to all patients enrolled in the study. The responses will be used by investigator 3 to calculate the QoR-15 Index, which summarizes the degree of patient satisfaction.

03

Conditions studied

  • RATS Surgery
  • Thymectomy
  • Locoregional Anesthesia
  • Postoperative Pain Management
  • Serratus Posterior Superior Intercostal Plane Block
  • Robotic-Assisted Thoracoscopic Surgery

Browse trials for

Keywords

  • SPSIP
  • RATS Thymectomy
  • Thymoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients affected by thymoma, thymic hyperplasia, or thymic pathologies (cysts, teratomas) who have given to the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse to participate in the study by not signing the ;
  • Patients with myasthenia gravis, severe obesity ( > 35), history of OSAS with or without CPAP;
  • Patients belonging to ASA classes > 3, according to the system developed by the ;
  • Patients unable to understand the functioning of the NPR Scale or the PCA device that will be used for postoperative analgesia;
  • Patients with allergies to analgesic and/or anesthetic drugs;
  • Patients on anticoagulant therapy;
  • Patients with a history of chronic pain;
  • Patients with an infection at the site where SPSIPB will be performed;
  • Patients who have had previous thoracic surgery and/or thoracic trauma with rib fractures on the side of the surgery;
  • Patients with chest deformities and/or neuromuscular diseases that interfere with normal ventilatory function.

Additionally, patients whose surgery is intraoperatively converted to sternotomy thymectomy will be excluded post-hoc from the study.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    SPSIP group

    Patients in this group will be treated with the Serratus Posterior Superior Intercostal Plane Block, administered under ultrasound guidance 15 minutes before surgery in the operating room. The block will be performed by administering 30 ml of 0.25% bupivacaine.

    Procedure: Ultrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with 0.25% bupivacaine

  • Placebo comparator
    Placebo group

    Patients in this group will be treated with the Serratus Posterior Superior Intercostal Plane Block, administered under ultrasound guidance 15 minutes before surgery in the operating room. The block will be performed using 30 ml of a placebo solution without an active ingredient (0.9% NaCl)

    Procedure: Ultrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with a placebo solution (0.9% NaCl)

Interventions

  • ProcedureUltrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with 0.25% bupivacaine

    While the patient is in the prone or the sitting position, a high-frequency linear transducer is placed transversely at the level of the scapular spine, visualizing the upper medial border of the scapula, trapezius muscle, rhomboid major, serratus posterior superior muscle, and the second and third ribs. Next, the transducer is rotated to obtain an oblique view, including the upper medial border of the scapula. The needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs to reach the fascial plane between the serratus posterior superior muscle and intercostal muscles using the in-plane technique. Once the needle contacts the rib, 30 mL of 0.25% bupivacaine is administered superficially to the intercostal muscle.

    Also known as: SPSIP Block with 0.25% bupivacaine

  • ProcedureUltrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with a placebo solution (0.9% NaCl)

    While the patient is in the prone or the sitting position, a high-frequency linear transducer is placed transversely at the level of the scapular spine, visualizing the upper medial border of the scapula, trapezius muscle, rhomboid major, serratus posterior superior muscle, and the second and third ribs. Next, the transducer is rotated to obtain an oblique view, including the upper medial border of the scapula. The needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs to reach the fascial plane between the serratus posterior superior muscle and intercostal muscles using the in-plane technique. Once the needle contacts the rib, 30 mL of 0.9% NaCl is administered superficially to the intercostal muscle

    Also known as: SPSIP Block with placebo solution (0.9% NaCl)

06

What researchers measure

Primary outcomes

  1. Postoperative pain intensity

    The measurement of postoperative pain intensity, assessed using the Numeric Pain Rating Scale (NPRS), a numerical scale that can range from 0 to 10 (where 0 means no pain and 10 corresponds to the worst imaginable pain), in the two study groups.

    Time frame: 0, 2, 6, 12, and 24 hours after the end of the surgical procedure

Secondary outcomes

  1. Total opioid drug consumption

    The total number of opioid doses administered via a Patient Controlled Analgesia (PCA) device in the first 24 hours after surgery

    Time frame: 24 hours after surgery

  2. Consumption of rescue analgesics

    The total dose of acetaminophen administered upon the patient's request during the first 24 postoperative hours

    Time frame: 24 hours after surgery

  3. postoperative respiratory complications

    The number of any postoperative respiratory complications in the two study groups

    Time frame: 24 hours after surgery

  4. postoperative quality of recovery

    the patient's level of satisfaction measured using the QoR-15 index, a numerical parameter calculated by administering the Quality of Recovery 15 (QoR-15) questionnaire to the patient

    Time frame: 24 hours after surgery

  5. Length of Hospital Stay

    the duration of postoperative hospitalization

    Time frame: from the end of the surgical procedure to patient discharge

07

Study locations

1 of 1 sites recruiting
  • Fondazione Policlinico A.Gemelli IRCCs
    Rome, 00135, Italy
    Recruiting
08

References and documents

Publications

  • Wang CQ, Wang J, Liu FY, Wang W. Robot-assisted thoracoscopic surgery vs. sternotomy for thymectomy: A systematic review and meta-analysis. Front Surg. 2023 Jan 6;9:1048547. doi: 10.3389/fsurg.2022.1048547. eCollection 2022. PubMed 36684131 ↗
  • Chao YK, Lee JY, Lu HI, Tseng YL, Lee JM, Huang WC. Robot-assisted surgery outperforms video-assisted thoracoscopic surgery for anterior mediastinal disease: a multi-institutional study. J Robot Surg. 2024 Jan 13;18(1):21. doi: 10.1007/s11701-023-01745-1. PubMed 38217569 ↗
  • Tulgar S, Ciftci B, Ahiskalioglu A, Bilal B, Sakul BU, Korkmaz AO, Bozkurt NN, De Cassai A, Torres AJ, Elsharkawy H, Alici HA. Serratus Posterior Superior Intercostal Plane Block: A Technical Report on the Description of a Novel Periparavertebral Block for Thoracic Pain. Cureus. 2023 Feb 3;15(2):e34582. doi: 10.7759/cureus.34582. eCollection 2023 Feb. PubMed 36883093 ↗
  • Avci O, Gundogdu O, Balci F, Tekcan MN, Ozbey M. Efficacy of serratus posterior superior intercostal plane block (SPSIPB) on post-operative pain and total analgesic consumption in patients undergoing video-assisted thoracoscopic surgery (VATS): A double-blinded randomised controlled trial. Indian J Anaesth. 2023 Dec;67(12):1116-1122. doi: 10.4103/ija.ija_589_23. Epub 2023 Dec 13. PubMed 38343684 ↗
  • Shintani Y, Funaki S, Ose N, Kanou T, Fukui E, Kimura K, Minami M. Surgical management of thymic epithelial tumors. Surg Today. 2021 Mar;51(3):331-339. doi: 10.1007/s00595-020-02070-y. Epub 2020 Jul 10. PubMed 32647929 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Mar 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Aug 9, 2024
StartActual
Mar 1, 2025
Primary completionEst.
Mar 15, 2026
CompletionEst.
Sep 15, 2026
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06545409
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Mar 1, 2025
Primary completion
Mar 15, 2026 (estimated)
Completion
Sep 15, 2026 (estimated)
Last update
Mar 25, 2025

Study contacts

Giovanni Punzo, MD
Contact
giovanni.punzo@policlinicogemelli.it
0630153212 ext. +39
Dania Nachira, MD
Contact
dania.nachira@policlinicogemelli.it
Giovanni Punzo, MD
principal investigator · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Dania Nachira, MD
principal investigator · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion